Type A influenza is the most common and most dangerous form of the flu virus. It’s the only type capable of causing pandemics, and it’s responsible for the majority of severe flu seasons. Unlike types B and C, influenza A circulates in both humans and animals, giving it a unique ability to mutate in ways that catch our immune systems off guard. Around a billion cases of seasonal flu occur worldwide each year, with 3 to 5 million of those classified as severe illness and 290,000 to 650,000 resulting in death from respiratory complications. Type A drives the bulk of that burden.
How Type A Differs From Other Flu Types
There are four types of influenza virus: A, B, C, and D. Types A and B cause the seasonal epidemics you hear about every winter. Type C causes mild illness and doesn’t trigger epidemics. Type D primarily affects cattle and isn’t known to infect people.
What sets type A apart is its range of hosts and its capacity for dramatic genetic change. Type B infects only humans. Type A circulates naturally in wild birds and has adapted to spread among pigs, horses, dogs, cats, seals, whales, chickens, and cows, in addition to people. This broad host range is what makes it so unpredictable. When a flu virus jumps from an animal population into humans, it’s always a type A virus.
Surface Proteins and Subtypes
Influenza A viruses are classified by two proteins that stud their outer surface: hemagglutinin (H) and neuraminidase (N). Hemagglutinin helps the virus latch onto your cells, and neuraminidase helps newly made copies of the virus break free to infect more cells. There are 18 known hemagglutinin subtypes and 11 neuraminidase subtypes, creating a large number of possible combinations. The subtypes you’ll see most often in flu season news are H1N1 and H3N2, the two that currently circulate in humans.
The virus itself carries its genetic instructions on eight separate segments of RNA. This segmented design is part of what makes influenza A so good at evolving, because those segments can be swapped between different strains when two viruses infect the same cell.
Why the Virus Changes So Quickly
Influenza A has two distinct ways of evolving, and understanding them explains why you can get the flu more than once and why vaccines need annual updates.
The first is called antigenic drift. Every time the virus copies itself inside your body, small mutations accumulate in the genes coding for its surface proteins. Over months and years, those tiny changes add up until the virus looks different enough that antibodies from your last infection or vaccination no longer recognize it well. Drift is the reason flu vaccines are reviewed and reformulated every year, and it’s why the flu keeps coming back each season even in populations with widespread prior exposure.
The second mechanism, antigenic shift, is far more abrupt and far more dangerous. Shift happens when an influenza A virus from an animal population acquires a completely new surface protein, or combination of proteins, that most humans have never encountered. Because almost nobody has existing immunity, a shifted virus can spread rapidly across the globe. This is how pandemics start. The 2009 H1N1 pandemic, for example, emerged when an H1N1 virus with gene segments from North American swine, Eurasian swine, human, and bird flu viruses began infecting people. Only four flu pandemics have occurred in the past century, but each was caused by an antigenic shift in a type A virus.
Symptoms and How It Spreads
Type A flu symptoms are what most people think of when they picture “the flu”: sudden onset of fever, chills, body aches, fatigue, cough, sore throat, and sometimes nasal congestion. Symptoms typically hit hard and fast, distinguishing flu from the gradual buildup of a common cold. Most healthy adults recover within one to two weeks, though fatigue can linger.
The virus spreads mainly through respiratory droplets produced when an infected person coughs, sneezes, or talks. You can also pick it up by touching a contaminated surface and then touching your mouth, nose, or eyes. People are most contagious in the first three to four days after symptoms appear, though they can spread the virus a day before feeling sick.
Complications After Infection
The most serious complication of influenza A is secondary bacterial pneumonia. After the virus damages the lining of your airways, bacteria that normally wouldn’t gain a foothold can take hold more easily. A study of patients at Veterans Affairs hospitals found that flu more than doubled the odds of developing a secondary infection with Streptococcus pneumoniae, one of the most common causes of bacterial pneumonia. About 10% of flu patients in that study later tested positive for this bacterium.
Other potential complications include sinus infections, ear infections (especially in children), worsening of chronic conditions like asthma or heart disease, and, in severe cases, inflammation of the heart or brain. People over 65, young children, pregnant women, and those with weakened immune systems face the highest risk of serious outcomes.
How Type A Flu Is Diagnosed
If you visit a clinic during flu season with classic symptoms, your provider may use a rapid influenza diagnostic test, which can return a result in about 15 minutes. These tests are good at confirming a positive result (95 to 99% accuracy for true positives), but they miss a substantial number of actual infections. Their sensitivity sits around 50 to 70%, meaning a negative result doesn’t rule out flu, especially when flu is circulating heavily in your community. The FDA now requires newer rapid tests to achieve at least 80% sensitivity.
More accurate molecular tests, which detect the virus’s genetic material, can also produce results within about 30 minutes and are increasingly available in clinics and emergency departments. These are considered the gold standard when a definitive answer matters for treatment decisions.
Antiviral Treatment
Four antiviral medications are currently recommended for treating influenza A in the United States. The most widely prescribed is oseltamivir (commonly known by the brand name Tamiflu), taken as a pill. Another option, baloxavir (Xofluza), works through a different mechanism and requires only a single dose. Two additional antivirals, zanamivir (inhaled) and peramivir (given by IV), are used less commonly.
These medications work best when started within 48 hours of symptom onset. They typically shorten illness by one to two days and reduce the risk of complications. Nearly all recently circulating seasonal influenza A strains remain susceptible to these drugs. An older class of antiviral, the adamantanes, once worked against type A but is no longer recommended because virtually all circulating strains have developed resistance to it.
One thing worth knowing: a specific genetic mutation called H275Y can make certain H1N1 strains resistant to oseltamivir. When this mutation is detected, providers may switch to baloxavir or another option that remains effective.
Vaccination
Annual flu vaccination is the primary tool for preventing influenza A. Because the virus drifts genetically each year, the vaccine composition is updated before every flu season. For the 2025–2026 season in the United States, flu vaccines are trivalent, meaning they protect against three viruses: an H1N1 strain, an H3N2 strain, and one influenza B virus.
The specific strains included differ slightly depending on how the vaccine is manufactured. Egg-based vaccines use H1N1 and H3N2 strains grown in eggs, while cell-based and recombinant vaccines use strains that more closely match what’s circulating because they avoid egg-adapted changes. Regardless of the manufacturing method, all approved vaccines target the same seasonal threats. Getting vaccinated each fall, ideally by the end of October, gives your immune system time to build protection before flu activity peaks in winter.